ArticleBMC microbiology2026
Genomic characterization of the multidrug-resistant IncP-2 plasmid pPAMS in a clinical isolate Pseudomonas aeruginosa.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe multidrug-resistant Pseudomonas aeruginosa represents a significant global public health threat, particularly strains associated with IncP-2 plasmids, which pose considerable challenges for clinical treatment. In this study, we conducted a comprehensive genomic characterization of the multidrug-resistant IncP-2 plasmid pPAMS, highlighting genomic diversity and molecular evolution of IncP-2 plasmids.
resultsWe identified an extensively drug-resistant P. aeruginosa strain, designated PAMS, which harbors an IncP-2 plasmid, referred to as pPAMS (448,129 bp). This plasmid contains 15 resistance genes, distribute in two multidrug resistance integrons (In786 and In1237), a cluster of RND efflux pump genes (tmexCD3-toprJ3), and a tetracycline resistance gene [tetA(C)]. Comparative analysis revealed that pPAMS and 20 megaplasmids shared high nucleotide identity and coverage in the NCBI database. The resistance region of pPAMS exhibited high similarity to previously reported plasmids pPA1609-475 and pBM413, sharing the same genetic architecture, with the exception of the genetic unit IS26-tetR(C)-tetA(C)-IS26. Notably, pPAMS possesses a unique variable region of approximately 20 kbp, contains the glycoside hydrolase 25, which may be associated with the microbial competition. Conjugation assays and antimicrobial susceptibility testing demonstrated that pPAMS could be transferred to P. aeruginosa PAO1, resulting in a multidrug-resistant phenotype. Additionally, virulence assays indicated that plasmid pPAMS could reduce bacterial pathogenicity, suggesting that it may repress the expression of virulence factors.
conclusionsThis study provides a comprehensive genetic analysis of the multidrug-resistant IncP-2 plasmid pPAMS. Our findings offer valuable insights into the genomic diversity and molecular evolution of IncP-2 plasmids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.